Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

112
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
112
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fractions of modifiable dementia risk factors in the Netherlands: a cross-sectional, time series analysis.

EClinicalMedicine·2026
Same author

Associations of cardiorespiratory fitness with structural brain networks in ageing: insights from The Maastricht Study.

GeroScience·2026
Same author

Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia: The HUNT Study.

Neurology·2026
Same author

What does it mean to be cognitively and socially active in the context of dementia risk reduction? An integrative review.

Aging & mental health·2026
Same author

Associations of the Lifestyle for Brain Health (LIBRA) index with cognitive functioning across adulthood: Variation by sex and socioeconomic status in the German National Cohort (NAKO).

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Towards specialized dementia risk reduction services for those with first cognitive symptoms: A mixed-method study into risk awareness, needs, and preferences among individuals with subjective cognitive decline and mild cognitive impairment from memory clinic and community settings and memory clinic professionals.

Journal of Alzheimer's disease : JAD·2026

Related Experiment Video

Updated: Jun 26, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Multidomain Dementia Risk Reduction in Primary Care is Feasible: A Proof-of-concept study.

Stephanie Van Asbroeck1, Sebastian Köhler1, Sophie C P M Wimmers1

  • 1Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Mental Health and Neuroscience (MHeNs) Research Institute, Maastricht University, Maastricht, the Netherlands.

Journal of Alzheimer'S Disease : JAD
|May 17, 2024
PubMed
Summary

Integrating dementia risk reduction into primary care is feasible, with a smartphone app enhancing knowledge. This approach supports public health goals for reducing dementia risk.

Keywords:
Alzheimer’s diseasedementiahealth behaviorlifestyleprevention and controlprimary health carerisk factorstelemedicine

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

2.9K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.3K

Related Experiment Videos

Last Updated: Jun 26, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

2.9K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.3K

Area of Science:

  • Public Health
  • Gerontology
  • Digital Health

Background:

  • Dementia risk reduction is a critical public health issue.
  • Accessible interventions for routine care are limited.

Purpose of the Study:

  • To assess the feasibility of integrating dementia risk reduction strategies into primary care.
  • To evaluate the added value of a smartphone application ('MyBraincoach') in this context.

Main Methods:

  • A cluster-randomized trial involving 188 participants (40-60 years) with modifiable dementia risk factors.
  • Practices were randomized to offer either a risk-reduction consultation alone or with the 'MyBraincoach' app.
  • Feasibility assessed via questionnaires and interviews after 3 months, with the primary outcome being the change in the "LIfestyle for BRAin health" (LIBRA) score.

Main Results:

  • Interventions were well-received, with 72.0% finding consultations informative and 69.2% deeming the app useful.
  • Low dropout rate (6.9%) and similar improvements in LIBRA scores, Mediterranean diet adherence, and BMI across both groups.
  • Increased knowledge of dementia risk reduction, particularly in the app group.

Conclusions:

  • Integrating dementia risk reduction into primary care, augmented by a smartphone app, is a viable strategy.
  • Further research is necessary to confirm the (cost-)effectiveness of this integrated approach.